Cargando…

Landscape of somatic mutations in different subtypes of advanced breast cancer with circulating tumor DNA analysis

It is particularly important to provide precise therapies and understand tumor heterogeneity based on the molecular typing of mutational landscape. However, the landscape of somatic mutations in different subtypes of advanced breast cancer (ABC) is largely unknown. We applied target-region capture d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yi, Zongbi, Ma, Fei, Li, Chunxiao, Chen, Rongrong, Yuan, Lifang, Sun, Xiaoying, Guan, Xiuwen, Li, Lixi, Liu, Binliang, Guan, Yanfang, Qian, Haili, Xu, Binghe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519668/ https://www.ncbi.nlm.nih.gov/pubmed/28729728 http://dx.doi.org/10.1038/s41598-017-06327-4

Ejemplares similares

Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study
por: Yi, Zongbi, et al.
Publicado: (2019)

Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients
por: Liu, Binliang, et al.
Publicado: (2022)

Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer
por: Yi, Zongbi, et al.
Publicado: (2020)

Gut Microbiota Profiling in Patients With HER2-Negative Metastatic Breast Cancer Receiving Metronomic Chemotherapy of Capecitabine Compared to Those Under Conventional Dosage
por: Guan, Xiuwen, et al.
Publicado: (2020)

Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers
por: Yi, Zongbi, et al.
Publicado: (2020)

Epithelial-Mesenchymal-Transition-Like Circulating Tumor Cell-Associated White Blood Cell Clusters as a Prognostic Biomarker in HR-Positive/HER2-Negative Metastatic Breast Cancer
por: Guan, Xiuwen, et al.
Publicado: (2021)

Genome-wide chromosomal instability by cell-free DNA sequencing predicts survival in patients with metastatic breast cancer
por: Mo, Hongnan, et al.
Publicado: (2020)

The association between early-onset cardiac events caused by neoadjuvant or adjuvant chemotherapy in triple-negative breast cancer patients and some novel autophagy-related polymorphisms in their genomic DNA: a real-world study
por: Liu, Binliang, et al.
Publicado: (2018)

Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer
por: Guan, Xiuwen, et al.
Publicado: (2019)

The molecular tumor burden index as a response evaluation criterion in breast cancer
por: Yi, Zongbi, et al.
Publicado: (2021)

Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China
por: Yi, Zongbi, et al.
Publicado: (2020)

The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma: A Meta-Analysis of Clinical Trials Following the PRISMA Guidelines
por: Guan, Xiuwen, et al.
Publicado: (2016)

Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells
por: Guan, Xiuwen, et al.
Publicado: (2016)

Antibody-drug conjugates in HER2-positive breast cancer
por: Li, Lixi, et al.
Publicado: (2022)

Plasma cell-free DNA and survival in non-small-cell lung cancer: A meta-analysis
por: Yi, Zongbi, et al.
Publicado: (2017)

Mutational characteristics determined using circulating tumor DNA analysis in triple‐negative breast cancer patients with distant metastasis
por: Rong, Guohua, et al.
Publicado: (2020)

ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy
por: Ma, Fei, et al.
Publicado: (2016)

DNA damage response as a prognostic indicator in metastatic breast cancer via mutational analysis
por: Rong, Guohua, et al.
Publicado: (2021)

Development and Validation of a New Clinical Prediction Model of Catheter-Related Thrombosis Based on Vascular Ultrasound Diagnosis in Cancer Patients
por: Liu, Binliang, et al.
Publicado: (2020)

The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial–mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer
por: Guan, Xiuwen, et al.
Publicado: (2019)

Breast Cancer in Chinese Females Aged 25 Years and Younger
por: Li, Lixi, et al.
Publicado: (2021)

Domain landscapes of somatic mutations in cancer
por: Nehrt, Nathan L, et al.
Publicado: (2012)

The somatic mutation landscape of the human body
por: García-Nieto, Pablo E., et al.
Publicado: (2019)

The somatic mutation landscape of premalignant colorectal adenoma
por: Lin, Shu-Hong, et al.
Publicado: (2018)

The somatic mutation landscape of Chinese Colorectal Cancer
por: Ma, Rong, et al.
Publicado: (2020)

The evolving landscape of prostate cancer somatic mutations
por: Cotter, Kellie, et al.
Publicado: (2022)

The landscape of somatic mutations in lymphoblastoid cell lines
por: Caballero, Madison, et al.
Publicado: (2023)

The landscape of somatic mutations in lymphoblastoid cell lines
por: Caballero, Madison, et al.
Publicado: (2023)

The landscape of somatic mutation in sporadic Chinese colorectal cancer
por: Liu, Zhe, et al.
Publicado: (2018)

The Somatic Mutation Landscape and RNA Prognostic Markers in Stomach Adenocarcinoma
por: Zhang, Xiulei, et al.
Publicado: (2020)

Cancer subtype identification using somatic mutation data
por: Kuijjer, Marieke Lydia, et al.
Publicado: (2018)

The somatic mutational landscape and role of the ARID1A gene in hepatocellular carcinoma
por: Meng, Guang-Xiao, et al.
Publicado: (2023)

Immune landscape and risk prediction based on pyroptosis-related molecular subtypes in triple-negative breast cancer
por: Luo, Lixi, et al.
Publicado: (2022)

Circulating Tumor Cells and Breast Cancer Metastasis: From Enumeration to Somatic Mutational Profile
por: Zhu, Chengjun, et al.
Publicado: (2022)

MEDULLOBLASTOMA EXOME SEQUENCING UNCOVERS SUBTYPE-SPECIFIC SOMATIC MUTATIONS
por: Pugh, Trevor J., et al.
Publicado: (2012)

Somatic mutation landscape of a meningioma and its pulmonary metastasis
por: Du, Yaran, et al.
Publicado: (2018)

The NF1 somatic mutational landscape in sporadic human cancers
por: Philpott, Charlotte, et al.
Publicado: (2017)

The Somatic Mutational Landscape of Mismatch Repair Deficient Prostate Cancer
por: Fang, Bangwei, et al.
Publicado: (2023)

Effects of psoriasis and psoralen exposure on the somatic mutation landscape of the skin
por: Olafsson, Sigurgeir, et al.
Publicado: (2023)

The landscape of somatic mutations in Infant MLL rearranged acute lymphoblastic leukemias
por: Andersson, Anna K, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_7unvicdcecka32s14voo4ostf3